Related Experiment Video
Updated: Aug 17, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
The emerging role of microRNA-4487/6845-3p in Alzheimer's disease pathologies is induced by Aβ25-35 triggered in
Ling Hu1,2, Rong Zhang2, Qiong Yuan2
1Department of Anesthesiology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, 430064, China.
Background:
Accumulation of amyloid β-peptide (Aβ) is implicated in the pathogenesis and development of Alzheimer's disease (AD). Neuron-enriched miRNA was aberrantly regulated and may be associated with the pathogenesis of AD. However, regarding whether miRNA is involved in the accumulation of Aβ in AD, the underlying molecule mechanism remains unclear. Therefore, we conduct a systematic identification of the promising role of miRNAs in Aβ deposition, and shed light on the molecular mechanism of target miRNAs underlying SH-SY5Y cells treated with Aβ-induced cytotoxicity.
Results:
Statistical analyses of microarray data revealed that 155 significantly upregulated and 50 significantly downregulated miRNAs were found on the basis of log2 | Fold Change | ≥ 0.585 and P < 0.05 filter condition through 2588 kinds of mature miRNA probe examined. PCR results show that the expression change trend of the selected six miRNAs (miR-6845-3p, miR-4487, miR-4534, miR-3622-3p, miR-1233-3p, miR-6760-5p) was consistent with the results of the gene chip. Notably, Aβ25-35 downregulated hsa-miR-4487 and upregulated hsa-miR-6845-3p in SH-SY5Y cell lines associated with Aβ-mediated pathophysiology. Increase of hsa-miR-4487 could inhibit cells apoptosis, and diminution of hsa-miR-6845-3p could attenuate axon damage mediated by Aβ25-35 in SH-SY5Y.
Conclusions:
Together, these findings suggest that dysregulation of hsa-miR-4487 and hsa-miR-6845-3p contributed to the pathogenesis of AD associated with Aβ25-35 mediated by triggering cell apoptosis and synaptic dysfunction. It might be beneficial to understand the pathogenesis and development of clinical diagnosis and treatment of AD. Further, our well-designed validation studies will test the miRNAs signature as a prognostication tool associated with clinical outcomes in AD.
Insights
Alzheimer's disease (AD) pathogenesis involves amyloid-beta (Aβ) and microRNAs (miRNAs). This study identifies two key miRNAs, hsa-miR-4487 and hsa-miR-6845-3p, involved in Aβ-induced cell apoptosis and synaptic dysfunction in AD.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Amyloid beta-peptide (Aβ) accumulation is central to Alzheimer's disease (AD) pathogenesis.
- Aberrant regulation of neuron-enriched microRNAs (miRNAs) is observed in AD, but their specific role in Aβ accumulation remains unclear.
- Understanding the molecular mechanisms of miRNA involvement in Aβ deposition is crucial for AD research.
Purpose of the Study:
- To systematically identify miRNAs involved in Aβ deposition.
- To elucidate the molecular mechanisms of target miRNAs in Aβ-induced cytotoxicity in SH-SY5Y cells.
- To investigate the role of specific miRNAs in Aβ-mediated pathophysiology.
Main Methods:
- Microarray analysis of miRNA expression in response to Aβ treatment.
- Quantitative real-time PCR (qRT-PCR) to validate miRNA expression changes.
- Assessment of cell apoptosis and axon damage in response to Aβ and miRNA modulation.
Main Results:
- Microarray analysis identified 155 upregulated and 50 downregulated miRNAs.
- hsa-miR-4487 was downregulated and hsa-miR-6845-3p was upregulated by Aβ25-35 in SH-SY5Y cells.
- Increased hsa-miR-4487 inhibited cell apoptosis, while decreased hsa-miR-6845-3p attenuated Aβ25-35-mediated axon damage.
Conclusions:
- Dysregulation of hsa-miR-4487 and hsa-miR-6845-3p contributes to AD pathogenesis via Aβ25-35, triggering cell apoptosis and synaptic dysfunction.
- These findings offer insights into AD pathogenesis, potentially aiding clinical diagnosis and treatment.
- Further validation studies will explore miRNA signatures as prognostication tools for AD clinical outcomes.
More Related Videos
07:55Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology